An open-label, randomized, multicenter study comparing the efficacy and safety of the combination of lasofoxifene and abemaciclib versus the combination of fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men with ER+/HER2− breast cancer with an ESR1 mutation.
Principal Investigator
Dott.ssa Vanesa Gregorc
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
The objective of the study is to compare the efficacy, safety, and tolerability of the combination of lasofoxifene and abemaciclib with those of fulvestrant and abemaciclib.
Pathologies
Breast Cancer
Medication
Lasofoxifene
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with locally advanced or metastatic ER+/HER2− breast cancer whose disease has progressed while taking an aromatase inhibitor (AI) in combination with palbociclib or ribociclib as first-line hormonal therapy for metastatic disease and who have an ESR1 mutation.
View the full study Back to search page